Major Backers Exit As Recursion Deepens Commitment To REC-102 Pipeline

Major investors Nvidia and Novo Holdings A/S have fully exited their positions in Recursion Pharmaceuticals (NasdaqGS:RXRX), signaling a shift in institutional backing. Recursion has acquired full ...

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial Results on February 25

Recursion will host a (L)earnings Call on February 25, 2026 at 8:00 am ET / 6:00 am MT / 1:00 pm GMT. The company will broadcast the live stream from Recursion’s X, LinkedIn, and YouTube accounts.

Recursion Pharmaceuticals to Report Q4 Earnings: What's in the Cards?

RXRX gears up for Q4 with $25.5 million revenue view as investors eye pipeline updates and REC-4881 progress ahead of FDA ...
Visual Studio Magazine

Decision Tree Regression from Scratch Without Pointers or Recursion Using C#

Dr. James McCaffrey presents a complete end-to-end demonstration of decision tree regression from scratch using the C# language. The goal of decision tree regression is to predict a single numeric ...

AI-Driven Bioengineering Platforms Revolutionize Protein, Strain, and Drug Design with Multi-Billion Dollar Government Support

Precedence Research, a leading strategic research firm, presents a comprehensive analysis of the AI-driven bioengineering ...
Morningstar

Rallybio Receives $12.5 Million Equity Milestone Payment from Recursion for Advancement of REV102 Program

The $12.5 million equity milestone payment is payable by Recursion pursuant to the previously announced agreement under which Rallybio sold its interest in the REV102 program to Recursion for up to ...
BioSpace

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – NEW HAVEN, Conn.--(BUSINESS WIRE)--Rallybio ...
Nasdaq

Recursion Acquires Full Ownership of ENPP1 Inhibitor Program REV102 from Rallybio for Hypophosphatasia Treatment

Recursion, a clinical-stage TechBio company, has successfully acquired Rallybio’s entire interest in their joint ENPP1 inhibitor program (REV102) aimed at treating hypophosphatasia (HPP), a rare ...
Nasdaq

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – The REV102 program originated from a joint venture ...
Morningstar

Rallybio Sells Interest in REV102 Program to Recursion Pharmaceuticals

– Company Eligible to Receive Up to $25 Million, Including an Upfront Equity Payment of $7.5 Million – – Extends Rallybio Cash Runway to Mid-2027 – Rallybio Corporation (Nasdaq: RLYB), a ...
IEEE

Synthesizing Recursive Logic Programs by Inverting General Resolution

Abstract: A fundamental scalability restriction of most Inductive Logic Programming (ILP) systems is that they search syntactically defined program spaces and cannot utilize relations in data. While ...